Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 168″]

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.